Your browser doesn't support javascript.
loading
Frequency of Intron 22 Inversion in Severe Hemophilia A Patients.
Ashfaq, Javeria; Ahmed, Rehana; Tariq, Faryal; Abedin, Qurat Ul; Abid, Madiha; Borhany, Munira.
Afiliação
  • Ashfaq J; Clinical Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
  • Ahmed R; Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
  • Tariq F; Clinical Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
  • Abedin QU; Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
  • Abid M; Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
  • Borhany M; Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
Cureus ; 14(8): e28247, 2022 Aug.
Article em En | MEDLINE | ID: mdl-36158401
ABSTRACT

OBJECTIVE:

The aim of our study was to find the frequency of Intron 22 inversion (Inv22) in severe hemophilia A (HA) patients and to evaluate the association between Inv22 and FVIII inhibitor formation.

METHOD:

Data analysis was carried out on IBM SPSS Statistics Version 23.00 (IBM Corp, Armonk, NY). Descriptive statistics were applied to measure the frequencies, percentages, and mean ± SD of the clinical and general history of HA patients, including age, family history, inhibitor status, intron22 inversion, and FVIII levels. Chi-square was applied to evaluate the association between Inv22 and F8 inhibitor formation.

RESULTS:

A total of 62 HA patients were enrolled in the study with mean±SD age of (14.39±13.2) years. A family history of HA was observed in 36 (58.1%) patients. Out of 62 patients, 28(45.2%) were reported as Inv22 positive while inhibitor status was observed as positive in three (4.83%) patients. However, an insignificant association was observed between the inhibitor and Inv22 positive patients with a p-value=0.443.

CONCLUSION:

In our study, Inv22 was found to be the major cause of severe HA in our patients, i.e., 45.1%. However, no significant relation was computed between Inv22 and inhibitor formation.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article